We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers.
- Authors
Tang, Yun-Hsin; Lin, Chiao-Yun; Lai, Chyong-Huey
- Abstract
With the advent of next-generation sequencing (NGS), The Cancer Genome Atlas (TCGA) research network has given gynecologic cancers molecular classifications, which impacts clinical practice more and more. New cancer treatments that identify and target pathogenic abnormalities of genes have been in rapid development. The most prominent progress in gynecologic cancers is the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors, which have shown breakthrough benefits in reducing hazard ratios (HRs) (HRs between 0.2 and 0.4) of progression or death from BRCA1/2 mutated ovarian cancer. Immune checkpoint inhibition is also promising in cancers that harbor mismatch repair deficiency (dMMR)/microsatellite instability (MSI). In this review, we focus on the druggable genetic alterations in gynecologic cancers by summarizing literature findings and completed and ongoing clinical trials.
- Subjects
GENETIC mutation; GYNECOLOGIC cancer; POLY ADP ribose; CARCINOGENESIS; IMMUNE checkpoint inhibitors; CANCER treatment; DNA mismatch repair
- Publication
Genes, 2021, Vol 12, Issue 10, p1593
- ISSN
2073-4425
- Publication type
Article
- DOI
10.3390/genes12101593